|
KMID : 0378019950380070067
|
|
New Medical Journal
1995 Volume.38 No. 7 p.67 ~ p.73
|
|
|
Study on The Clinical Effect of Relafen^(®)(Nabumetone)
|
|
|
|
|
Abstract
|
|
|
Background : Background: Levofloxacin, oral fluoroquinolone antibacterial agents, has potential as a broad spectrum antibacterial drug in the treatment of a variety of infections. Levofloxacin, the optically active L-isomer of ofloxacin, is active against most aerobic Gram-positive and Gram-negative organisms, being two- to fourfold more active than ofloxacin. The rate of bacteriological efficacy for levofloxacin ranged from 81 to 100% for Hemophilus influenzae and Pneumococcus pneumoniae, which are commonly isolated organisms in community-aquired pneumonia. Therefore, we attempted to investigate the therapeutic efficacy and tolerability of levofloxacin in patients with acute or chronic lower respiratory tract infections.
Method : Levofloxacin(CRAVIT?)300mg/day was administrated for 10?30 days in 17 patients with acute or chronic lower respiratory tract infections of mild to moderate severity. Clinical efficacy was determined using the frequency of cough, the volume of sputum per day, the property of sputum, the total leucocyte counts in blood, ESR, and radiological changes. And also, we evaluated clinical adverse events and effects on laboratory indices.
Results :
1. The severity of coughing was significantly attenuated from the scores of 1.76±0.66 to 1.17± 0.80 with levofloxacin(CRAVIT?) treatment(p < 0.01).
2. The daily amount of expectorated sputum was significantly reduced(p < 0.01).
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|